Vertex Completes Redemption of Convertible Senior Subordinated Notes
CAMBRIDGE, Mass. -- June 18, 2013
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has
completed its previously announced call for redemption of $400 million in
aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due
2015. Holders of $400 million in aggregate principal amount of the 2015 Notes
converted their 2015 Notes into approximately 8.3 million shares of common
stock prior to the June 17, 2013 redemption date. With the completion of this
transaction, Vertex has no outstanding convertible debt.
Vertex creates new possibilities in medicine. Our team discovers, develops and
commercializes innovative therapies so people with serious diseases can lead
Vertex scientists and our collaborators are working on new medicines to cure
or significantly advance the treatment of hepatitis C, cystic fibrosis,
rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, Mass., we now have ongoing
worldwide research programs and sites in the U.S., U.K. and Canada. Today,
Vertex has more than 2,000 employees around the world, and for three years in
a row, Science magazine has named Vertex one of its Top Employers in the life
(VRTX - GEN)
Michael Partridge, 617-341-6108
Kelly Lewis, 617-961-7530
Zach Barber, 617-341-6470
Press spacebar to pause and continue. Press esc to stop.